Efficacy of early Helicobacter Pylori eradication versus continuous pantoprazol Infusion in prevention of rebleeding in peptic ulcer patients

Efficacy of early Helicobacter Pylori eradication versus continuous pantoprazol infusion in prevention of rebleeding in peptic ulcer patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201108073836N2

Enrollment

102

Registered

2011-08-23

Start date

2011-12-14

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peptic ulcer-GI bleeding. Gastric ulcer -Duodenal ulcer -Acute with haemorrhage

Interventions

Intervention 1: Group H (control group) will be treated by Omeprazole 20mg two times a day(BID), subcytrate bismuth 240mg BID, metronidazole 500mg BID and tetracycline 1000mg BID for 14 days. Interven

Treatment - Drugs

Group H (control group) will be treated by Omeprazole 20mg two times a day(BID), subcytrate bismuth 240mg BID, metronidazole 500mg BID and tetracycline 1000mg BID for 14 days

The group P (case) will receive pantoprazol 80 mg intravenously, stat and then 8mg/h infusion for 72 hours

Eligibility

Sex/Gender

All

Age

16 Years to 89 Years

Inclusion criteria

Inclusion criteria: The bleeding peptic ulcer patients with age = 16 y old who have stigmata of recent bleeding like active spurting ( Forrest IA), non bleeding visible vessel ( Forrest IIA), oozing or adherent clot with visible vessel ( Forrest IA, IB, IIA) will be included in study. The exclusion criteria are: esophageal varicose, liver cirrhosis, malignancy, concomitant morbidity, cardiac pacemaker, NSAID consumption, current therapy with anti coagulant, antibiotic or PPI and multiple ulcers.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Surgery. Timepoint: One Week. Method of measurement: Number.;Transfustion. Timepoint: One week. Method of measurement: Number.;Mortality. Timepoint: One week. Method of measurement: Number.;Duration of admission. Timepoint: One week. Method of measurement: Day.;Rebleeding. Timepoint: One week. Method of measurement: Hematemesis, Repeating melena, >2gr/dl Decrease in Hb level, Pulse rate > 90/min or sudden drop in blood pressure.	—

Measure

Time frame

Surgery. Timepoint: One Week. Method of measurement: Number.;Transfustion. Timepoint: One week. Method of measurement: Number.;Mortality. Timepoint: One week. Method of measurement: Number.;Duration of admission. Timepoint: One week. Method of measurement: Day.;Rebleeding. Timepoint: One week. Method of measurement: Hematemesis, Repeating melena, >2gr/dl Decrease in Hb level, Pulse rate > 90/min or sudden drop in blood pressure.

—

Secondary

Measure	Time frame
Rebleeding. Timepoint: 0ne month. Method of measurement: Hematemesis, Repeating melena, >2gr/dl Decrease in Hb level, Pulse rate > 90/min or sudden drop in blood pressure.;Surgery. Timepoint: One month. Method of measurement: Number.;Transfustion. Timepoint: One month. Method of measurement: Number.;Mortality. Timepoint: One month. Method of measurement: Number.;Duration Admission. Timepoint: One month. Method of measurement: Day.	—

Measure

Time frame

Rebleeding. Timepoint: 0ne month. Method of measurement: Hematemesis, Repeating melena, >2gr/dl Decrease in Hb level, Pulse rate > 90/min or sudden drop in blood pressure.;Surgery. Timepoint: One month. Method of measurement: Number.;Transfustion. Timepoint: One month. Method of measurement: Number.;Mortality. Timepoint: One month. Method of measurement: Number.;Duration Admission. Timepoint: One month. Method of measurement: Day.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAbdolrahim Masjedizadeh

Imam Hospital

rmasjedi@hotmail.com+98 61 1222 2922

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026